Pfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO (elranatamab-bcmm) in patients with relapsed or refractory multiple myeloma (RRMM), who are heavily pretreated. ELREXFIO is a …
A groundbreaking trial has discovered that two drugs typically used to strengthen immune systems can also help in the fight against bowel cancer when combined. Researchers at Anglia Ruskin University …
The company has unveiled significant findings from its first-in-human phase 1 trial of KNS366, its leading drug candidate. The trial focused on assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of …